¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"RNA (New York, N.Y.)"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • precusor messenger RNA
    Àü·É(îîÖµ)RNA Àü±¸Ã¼(îñÏÌô÷)
  • precursor ribosomal RNA
    ¶óÀ̺¸¼Ø RNA
  • precursor transfer RNA
    Àü´Þ(îîÓ¹) RNA Àü±¸Ã¼(îñÏÌô÷)
  • preearly RNA
    ÀüÁ¶±â(îñðÄÑ¢) RNA
  • pre-messenger RNA
    Àü±¸ Àü·É(îñÏÌîîÖµ)RNA
  • prereplicative RNA
    º¹Á¦Àü(ÜÜð²îñ) RNA
  • pre-ribosomal RNA
    Àü±¸(îñÏÌ)¶óÀ̺¸¼Ø RNA
  • pre-transfer RNA
    Àü±¸(îñÏÌ)ÀüÀÌ(ï®ì¹)RNA
  • pseudomessenger RNA
    À§Àü·É(êÊîîÖµ) RNA
  • pulse-labeled RNA
    ÆÞ½º Ç¥Áö(øöò½) RNA
  • rapidly labeled RNA
    ±ÞÈ÷ Ç¥Áö(øöò½)µÈ RNA
  • recombinant RNA technique
    ÀçÁ¶ÇÕ(î¢ðÚùê) RNA ¼ú(âú)
  • ribosomal precursor RNA
    ¶óÀ̺¸¼Ø Àü±¸(îñÏÌ) RNA
  • ribosomal RNA
    ¶óÀ̺¸¼Ø RNA
  • RNA
    (å²) Ribonucleic acid
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
TRNB Transient Respiratory distress of New Born
TTNB Transient Tachypnea of New Born
ANDA Abbreviated New Drug Application
IND indomethacin; industrial medicine; investigational new drug
NAD neutrophil actin dysfunction; new antigenic determinant; nicotinamide adenine dinucleotide; nicotini...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
RDRP RNA dependent RNA polymerase
sat RNA satellite RNA
n-RNA nuclear RNA
NJ A/New Jersey
IND Investigational New Drug
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
messenger RNA <molecular biology> Single stranded RNA molecule that specifies the amino acid sequence of one or more polypeptide chains. This information is translated during protein synthesis when ribosomes bind to the mRNA.
In prokaryotes, mRNA is normally formed by splicing a large primary transcript from a DNA sequence and protein synthesis starts while the mRNA is still being synthesised. Prokaryote mRNAs are usually very short lived (average t 1/2 is 5mins.).
In contrast, in eukaryotes the primary transcripts (HnRNA) are synthesised in the nucleus and they are extensively processed to give the mRNA that is exported to the cytoplasm where protein synthesis takes place.
This processing includes the addition of a 5' 5' linked 7 methyl guanylate cap at the 5' end and a sequence of adenylate groups at the 3' end, the poly A tail, as well as the removal of any introns and the splicing together of exons, only 10% of HnRNA leaves the nucleus.
Eukaryote mRNAs are comparatively long lived with a half life ranging from 30minutes to 24 hours.
(27 Jun 1999)
GTP-RNA guanylyltransferase <enzyme> Catalyses addition of GMP residue to 3'-ends of oligonucleotide primers
Registry number: EC 2.7.7.-
Synonym: terminal guanylyltransferase
(26 Jun 1999)
RNA <molecular biology> A nucleic acid found in all living cells. Plays a role in transferring information from DNA to the protein-forming system of the cell.
(16 Dec 1997)
RNA 2'-O-methyltransferase <enzyme> Methylates 2'-hydroxyl group of ribose moieties of ribosomal RNA; highest activity poly (c) is a synthetic substrate
Registry number: EC 2.1.1.-
Synonym: nucleolar 2'-o-methyltransferase
(26 Jun 1999)
RNA 3'-terminal phosphate cyclase <enzyme> ATP dependent; forms 2',3' terminal cyclic phosphate on RNA which is then the substrate for RNA ligase of hela cells
Registry number: EC 6.5.-
Synonym: RNA tph cyclase
(26 Jun 1999)
RNA, antisense An RNA molecule which, by binding to a complementary sequence in either RNA or DNA, inhibits the function and/or completion of synthesis of the latter molecule. It is involved in various regulatory systems in vivo. Artificial antisense rnas have been used to inhibit translation of specific mRNA molecules both in living cells (eukaryotic and bacterial) and in cell-free systems.
(12 Dec 1998)
RNA, archaeal Ribonucleic acid in archaea having regulatory and catalytic roles as well as involvement in protein synthesis.
(12 Dec 1998)
RNA, bacterial Ribonucleic acid in bacteria having regulatory and catalytic roles as well as involvement in protein synthesis.
(12 Dec 1998)
RNA-binding proteins Proteins which bind to RNA molecules. Certain structure motifs are common to several of the proteins, such as arginine (arg)-rich tracts, typically consisting of alternating arg-asp, arg-ser, or arg-gly residues. These proteins also tend to have a common ribonucleotide sequence domain.
(12 Dec 1998)
RNA cap analogs Analogs of RNA cap compounds which do not have a positive charge. These compounds inhibit the initiation of translation of both capped and uncapped messenger RNA.
(12 Dec 1998)
RNA caps Compounds with the general structure 7-methyl-5'-guanosine triphosphate-5'-x which modify the 5' end of eukaryotic cellular and viral messenger RNA and some heterogeneous nuclear rnas. These compounds, which are positively charged, protect the above specified rnas at their termini against attack by phosphatases and other nucleases and promote mRNA function at the level of initiation of translation. Analogs of the RNA caps (RNA cap analogs), which lack the positive charge, inhibit the initiation of protein synthesis.
(12 Dec 1998)
RNA, catalytic RNA which contains an intron sequence that has an enzyme-like catalytic activity. This intron sequence has been shown to fold up to form a complex surface that can function like an enzyme in reactions with other RNA molecules and thus synthesise new molecules even in the absence of protein.
(12 Dec 1998)
RNA, chloroplast Ribonucleic acid in chloroplasts having regulatory and catalytic roles as well as involvement in protein synthesis.
(12 Dec 1998)
RNA, complementary Synthetic transcripts of a specific DNA molecule or fragment, made by an in vitro transcription system. This crna can be labelled with radioactive uracil and then used as a probe.
(12 Dec 1998)
RNA-dependent ATPase <enzyme> Requires single-stranded polynucleotide as cofactor
Registry number: EC 3.6.1.-
Synonym: atpase, RNA-dependent
(26 Jun 1999)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • New Federalism
    ½Å¿¬¹æÁÖÀÇ
  • New Frontier
    ´º ÇÁ·ÐƼ¾î(¹Ì±¹ ´ëÅë·É Á¸ ¿¡ÇÁ ÄɳʵðÀÇ Àû±ØÀûÀÎ Á¤Ã¥)Frontier
  • New Guinea
    ¿À½ºÆ®·¹Àϸ®¾Æ ºÏºÎÀÇ ¼¶
  • New Hampshire
    ¹Ì±¹ºÏµ¿ºÎÀÇ ÁÖ;´ºÇÜÇÁ¼Å
  • New Jersey
    (´©ÀúÁö)À̶¥À» ¹ÞÀº ¿µ±¹Á¦µ¶ÀÇ Ãâ½ÅÁö;Jersey¼¶ÀÇ À̸§À» µû¼­);¹Ì±¹ µ¿ºÎÀÇ ÁÖ
  • New Jerusalem
    »õ·Î¿î;¿¹·ç»ì·½;¼­¿Â;¿äÇÑ °è½Ã·Ï;Áö»ó³«¿ø;õ±¹
  • New Journalism
    ½Å Àú³Î¸®Áò(°´°ü¼º)°£°á¼º À§ÁÖÀÇ Á¾·¡ Àú³Î¸®Áò¿¡ ´ëÇÏ¿© ±âÀÚÀÇ ÁÖ°üÀû Âü°¡ ½É¸®Àû ÃßÃøµîÀÌ Æ¯Â¡)
  • New Journalist
    ½ÅÀú³Î¸®Áò ±âÀÚ(¸®Æ÷Æ®)
  • New Latin
    ±Ù´ë¶óƾ¾î
  • New Learning
    ½ÅÇй®;Çп¹ ºÎÈï(¹®¿¹ºÎÈïÀÇ ÀÚ±ØÀ» ¹Þ°í ÀϾ °í´ë ±×¸®½º ¹®¿¹ÀÇ ¿¬±¸)
  • New Left
    ½ÅÁÂÀÍ;´º·¹ÇÁÆ®(1960)³â ÀÌÈÄ ÀÎÁ¾ ÅëÇÕ;±ººñ Ãà¼Ò;¹ÝÀüµî ±ÞÁøÀû »çȸ °³ÇõÀ» ºÎ¸£Â¢´Â ÀÚÀ¯ÁÖÀÇ Áö½ÄÃþ
  • New Mexican
    ´º¸ß½ÃÄÚÁÖÀÇ(»ç¶÷)
  • New Mexico
    ´º¸ß½ÃÄÚ;¹Ì±¹ ³²¼­ºÎÀÇ ÁÖ
  • New Moon
    Ãʽ´Þ(È÷ºê¸®ÀÎ)½Å¿ùÁ¦
  • New Orleans
    ´º¿Ã¸®¾ð½º(¹Ì±¹Mississippi °­º¯ÀÇ Ç×±¸µµ½Ã)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á